Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

FDA Approves ZembraceSymTouch

Injectable sumatriptan succinate for migraine

Publish date:: February 9, 2016

Dr. Reddy's Laboratories announced that FDA has approved ZembraceSymTouch (sumatriptan succinate) injection, a drug-device combination product intended for the treatment of acute migraine episodes, with or without aura, in adults who are inadequately managed with existing treatment regimens. ZembraceSymTouch is available as a prefilled, ready-to-use, single-dose disposable autoinjector containing 3 mg of sumatriptan, a selective 5-HT1B/ID receptor agonist. The injection is intended to be given subcutaneously.

Citation: Dr. Reddy’s Laboratories Ltd. receives FDA approval for ZEMBRACESymTouch (sumatriptan succinate) injection for the acute treatment of migraines in adults. [news release]. Princeton, NJ: Dr. Reddy’s Laboratories; January 29, 2016. http://www.drreddys.com/media/215069/press-release-zembrace-symtouch_29-jan-2016.pdf. Accessed February 4, 2016.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in FDA Actions

FDA Approves Inbrija for PD OFF Episodes, Acorda Therapeutics news release; 2018 Dec 21

FDA Approves Firdapse for Rare Autoimmune Disorder, FDA news release; 2018 Nov 28

FDA Approves Ajovy for Migraine in Adults, Teva Pharmaceutical news release; 2018 Sep 14

FDA Approves Tiglutik for Treatment of ALS, ITF Pharma news release; 2018 Sep 6

FDA Approves Diacomit for Treatment of Seizures, Biocodex news release; 2018 Aug 23